Horizon Discovery

Horizon Discovery

Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation.

Telephone: +44 (0)1223 976 000
Address: Building 8100, Cambridge Research Park, Waterbeach
Postcode: CB25 9TL
Country: United Kingdom
Website: http://www.horizondiscovery.com
Membership type:Founder Member

Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation.

Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer. Horizon offers a catalogue of over 1,000,000 cell and reagent products, which along with related research services, support a greater understanding of the function of genes across all species and the genetic drivers of disease, and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, and are used in the Company’s own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”. www.horizondiscovery.com

Horizon Discovery partners with Biocartis to provide reference standards for Idylla™ assay

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has developed a set of precisely defined cell line-derived reference standards to support Biocartis’ recently launched Idylla™ microsatellite instability (MSI) Assay (1).

1 November 2018Read in full

Horizon Discovery Myeloid DNA Reference Standard supports genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. It is the first-to-market large cell line-derived reference standard for myeloid blood cancers.

24 September 2018Read in full

Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s drive to establish a functional genomics discovery platform.

14 September 2018Read in full

Horizon Discovery announces collaboration on single cell RNAseq-linked CRISPR screening

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.

28 August 2018Read in full

Terry Pizzie

Horizon Discovery appoints Terry Pizzie as Chief Executive Officer

Horizon Discovery Group plc), a global leader in gene editing and gene modulation technologies, is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.

8 May 2018Read in full

Horizon and Pirbright Institute support research into improvement of vaccine yields

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that it has extended its biomanufacturing capabilities through an agreement with The Pirbright Institute to jointly work on a research programme aimed at deploying cell engineering to increase the yields of livestock vaccines.

12 April 2018Read in full

Horizon Discovery’s Bioproduction cell line used as part of a successful drug (IND) filing

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND) filing with the United States Food and Drug Administration (USFDA).

22 March 2018Read in full

Horizon Discovery announces leadership changes

Horizon Discovery Group plc (LSE: HZD), a global leader in gene editing and gene modulation technologies, today announces that Dr Darrin M. Disley has decided to step down as Chief Executive Officer in order to pursue other business interests.

20 February 2018Read in full

Activation of IL1R2 with Edit-R CRISPRa

Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from its recently acquired Dharmacon™ business. This is the latest addition to the company’s market-leading Edit-R™ portfolio for CRISPR-Cas9 genome engineering.

14 November 2017Read in full

Horizon Discovery partners with The Michael J. Fox Foundation for Parkinson’s research

Horizon Discovery partners with The Michael J. Fox Foundation for Parkinson’s research

Horizon Discovery, a global leader in gene editing and gene modulation technologies, in partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF), today introduced two new gene knock-out and knock-in rat models for investigating the role of alpha-synuclein in brain function and Parkinson’s disease (PD) pathogenesis.

31 October 2017Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. ...
  12. 21